PARIS―Mauna Kea Technologies, a producer of endomicroscopy products, this week announced that the American Medical Association's CPT (current procedural terminology) editorial panel has approved three Category I codes to cover use of Cellvizio in the gastrointestinal tract. The company contests that customers will be able to use these codes to facilitate the claims and reimbursement process when utilizing Cellvizio.
Cellvizio, the world's smallest microscope, is the first system designed to provide live cellular-level images of internal human tissues during endoscopic procedures, according to Mauna Kea Technologies.
"The AMA CPT editorial panel's approval of Category I codes for Cellvizio represents an important step in our efforts to advance endomicroscopy and become a standard of care in gastroenterology," said Sacha Loiseau, founder and CEO of Mauna Kea Technologies.
"We believe that these new codes, once implemented early next year, will allow more patients with suspected GI disease to have access to our technology," Loiseau continued. "Studies have shown that with cellular level views of the GI tract, physicians have more information to help them identify early signs of disease and make more informed treatment decisions at the patient's bedside."